Women's health leader Hologic has acquired Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for approximately $808 million.
Mobidiag provides near-patient, molecular diagnostic instruments and tests for acute care conditions including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections.
“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic, in a statement. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”
Mobidiag's Amplidiag and Novodiag testing platforms deliver results in 50 minutes to two hours. The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing. Multiplexing enables multiple pathogens to be identified in a single sample, streamlining workflows for laboratories and providing rapid results to physicians.
In January, Hologic acquired Biotheranostics Inc.
, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million.
Also in January, the company acquired SOMATEX Medical Technologies
, a developer of biopsy site markers and localization technologies, for approximately $64 million.